Long-Term Study of IGIV, 10% in Alzheimer´s Disease
Stopped early · Phase 3
Conditions studied: Alzheimer´s Disease
In brief
The purpose of this long-term study is to provide additional evidence of safety and efficacy of IGIV, 10% treatment in participants with Alzheimer´s Disease who have completed the Phase 3 Baxter precursor study 160701. All participants will receive IGIV, 10% at either 0.2 g/kg or 0.4 g/kg body weight depending on their treatment assignment in Baxter study 160701. Participants and investigators will be blinded to dose unless otherwise notified by the sponsor.
Key facts
- Study ID
- NCT01736579
- Run by
- Baxalta now part of Shire
- People needed
- 6
- Starts
- 2012-11-29
- Expected to finish
- 2013-06-04
- Last updated by the study team
- 2021-05-19
Who can join
Age: 51 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Study site — Rochester, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.